| Name | Title | Contact Details |
|---|
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
CP OF BOZEMAN is a Cascade, MT-based company in the Business Services sector.
Mary Washington Health Alliance is physician led, physician governed integrated network of 400 physicians covering more than 80,000 lives throughout the Rappahannock region of Virginia, between Richmond and Washington D.C. The broad reach of physician leadership and governance has important implications on how effective Population Health Management is adopted successfully. These Population Health management strategies include incorporating evidence-based information more quickly into patient diagnosis and treatment, engaging patients and families more directly in care, delivering higher levels of team-based care, and providing more-transparent cost and quality data to physicians and other providers. As the country moves away from fundamental fee-for-service payments, successful ‘interdependence between hospitals and physicians becomes necessary in defining a clinically integrated delivery system that gets reimbursed for keeping the community healthy. MWHA has built on Mary Washington Healthcares (MWHC) rich 100 year history through partnerships with key stakeholders who share a common mission of improving the health of the population they serve. After completing (3) consecutive years in the Medicare Shared Savings Program and having shown savings and improved quality of care, the Alliance is ready to take on the road ahead within the Next Generation ACO! As 1 of 51 participants in the Next Generation ACO Model, MWHA will be able to build on the current level of coordinated care and will provide an enhanced quality of care at lower costs to Medicare patients. By partnering with their patients in care decisions, NGACO Participants will achieve the goals of better health and better care for Medicare beneficiaries.
The LMLA Mission is to provide all employees with leadership development opportunities in support of the Lockheed Martin vision.
Mainliner Freightways Ltd. is a Mississauga, ON-based company in the Business Services sector.